Introduction
Dependent on additional risk factors the incidence of Epstein-Barr virus(EBV)-associated post-transplant lymphoproliferative disease (PTLD) varies from 1-25% [1] [2] [3] [4] . A significantly increased incidence of PTLD after allogeneic HSCT was reported in patients with T cell depleted grafts, after intensive treatment of graft-versus-host-disease (GvHD), and in cases with advanced stages of acute GvHD (grades 3 or 4) [3, 5] . The pathogenetical model for the development of PTLD includes the increased proliferation of EBV-infected B lymphocytes and its insufficient immune control by T cells. In addition, genetic mutations in infected proliferating B lymphocytes lead to transformed malignant cells and the development of aggressive malignant lymphoma [6] . Both clinical course as well as morphology of these disorders are very heterogenous [3] . However, there is a high frequency of extranodal involvement [6] . Treatment strategies include withdrawal of immunosuppression [3] , infusion of unselected donor leukocytes or EBV-specific cytotoxic donor T cells [1, [7] [8] [9] , application of antiviral drugs and combination chemotherapy [10] [11] [12] [13] . Moreover, the use of specific anti-Bcell monoclonal antibodies (anti-CD20, -CD21, -CD24) was intensively examined over the last years [4, [14] [15] [16] [17] . We here report the successful treatment of an EBV-associated PTLD including CNS involvement with the combination of anti-CD20 monoclonal antibody Rituximab and antiherpesvirus agent Cidofovir.
Case Report
A 24-year-old female patient with acute T-lymphoblastic leukemia in second complete remission received T-cell depleted, HLA-DRQB1-micromismatched HSCT from an unrelated donor in February 1999. Conditioning regimen consisted of 1200 cGy fractionated total body irradiation, cyclophosphamide (60 mg/kg × 2), etoposide (30 mg/kg × 1) and antithymocyte globulin (ATG) Merieux (2.5 mg/kg × 4). The graft contained 8.8 × 10 6 /kg CD34-positive cells. Following transplantation the patient received T-cell addback consisting of 1 × 10 5 /kg and 1 × 10 6 /kg CD3-positive cells, respectively, on days +14 and +21. GvHD prophylaxis was performed from day +15 to day +100 only with cyclosporine (CSA). Subsequently various complications as consequence of the immunodeficiency were diagnosed (esophagitis caused by reactivated CMV infection, ambilateral pneumonia with suspicion of aspergillosis, maxillary sinusitis). 9 months after transplantation the patient developed a histologically proven chronic GvHD of the skin and gastrointestinal tract (extensive disease) that was successfully treated with prednisolone. Because of unacceptable side effects (muscular atrophy, depression, insomnia) the application of prednisolone had to be stopped and from day +210 the immunosuppression was continued with CSA. 4 months later (day +312) the patient had to be admitted to hospital with peripheral lymphomas, B symptoms (fever up to 40 °C, weight loss of 6 kg in 3 months) and physical weakness. Neurological symptoms including tremor, hypersensitivity to light and touch, imbalances and insecurity in walking were observed. An ultrasound scan showed enlarged lymph nodes (cervical, axillary, inguinal) up to 2.4 cm in diameter. As signs of increased cell proliferation lactate dehydrogenase (LDH) as well as thymidine kinase (TK) levels in . Subsequently we observed a rapid improvement of the general condition of the patient with complete regression of the peripheral lymphomas and disappearance of the neurological symptoms. The patient was discharged from hospital on day +338. The PCR control on EBV-DNA first became negative only in the plasma while it still remained positive in CSF (day +337). Therefore, we continued outpatient the application of Cidofovir on days +348 and +362. Subsequently, also in CSF the PCR on EBV-DNA became negative (day +378). Until day +440 the patient remained well without any signs of a nodular or CNS relapse of the EBV-lymphoma. However, an ambilateral pneumonia caused by Aspergillus fumigatus was diagnosed. After development of an ARDS the patient died on day +458 as a consequence of a multiorgan failure.
Discussion
EBV-associated PTLD is a serious complication in patients with allogeneic HSCT after myeloablative as well as after dose-modified conditioning. Treatment of choice is immunotherapy with immediate withdrawal of immunosuppression on the one hand and infusion of unselected donor leukocytes or EBV specific cytotoxic donor T cells on the other hand [1, 3, 8] . However, the potential alloreactivity of unmanipulated donor cells as well as the problems of a immediate availability of unrelated donors can limit this therapeutic option [1, 7] . Beside cytotoxic agents and various antiviral drugs [10] [11] [12] [13] , positive results of the use of the monoclonal anti-CD20 antibody rituximab were repeatedly reported [4, 16, 17] . The situation of our patient with CNS involvement appeared difficult for different reasons. First, beside the discontinuation of the immunosuppression an intensive immunotherapy (including DLI) was impossible (preexisting GvHD, unrelated donor). Treatment with chemotherapeutic agents was not likely to be successful, since the results in patients with PTLD are frequently unsatisfactory [6, 18] . On the other hand a very limited number of cytotoxic drugs are able to cross the bloodbrain barrier [19] . Although the ability to penetrate into the CNS is unknown with Rituximab [19, 20] , we decided to use this antibody because of its repeatedly reported effectiveness in EBV-associated PTLD [4, 16, 17] . In addition, in patients with CNS involvement by B-cell lymphoma the systemic and/or intraventricular application of Rituximab were described occasionally [20] [21] [22] [23] [24] . We combined Rituximab with Cidofovir, its antiviral efficiency against EBV having been already examined [25, 26] . The clinical course of our patient could indicate that Rituximab is effective not only in cases with nodular manifestation of EBV-LPD. We have seen that this antibody is active also in CNS despite low concentrations in the CSF in comparison to serum levels described by several authors [20, 22, 24] .
Conclusion
As seen in our patient with meningeosis lymphoblastica caused by a malignant EBV-associated lymphoma, it is possible to achieve complete remission without any systemic or intrathecal cytotoxic chemotherapy. This shows that the disturbance of the blood-brain-barrier, frequently observed in patients with CNS involvement, seems to play an important role. Therefore, the systemic use of Rituximab in conventional doses appears to be an interesting alternative treatment in patients with EBV-associated PTLD and CNS involvement. 
